MedTrace Logo

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

NCT03028987 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-09-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important factors of influenza immunity especially of or specific proteins associated with the T-cell immune response.

Conditions

Interventions

BIOLOGICAL

Fluzone®

Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)

BIOLOGICAL

FluMist®

FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Mark Davis, PhD · Stanford University

  • K. Christopher Garcia, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-19
Primary Completion
2015-11-18
Completion
2015-11-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03028987 on ClinicalTrials.gov